mounjaro tirzepatide weight loss Eli Lilly launches weight-loss drug

What are the potential long-term benefits of FDA-approved oral semaglutide

Its worth noting that these positive effects were only seen in patients taking long-acting GLP-1 receptor agonists (more commonly prescribed) and not in those using short-acting agents

Tirzepatide (Mounjaro and Zepbound) produces larger total weight loss than semaglutide on average, which means larger absolute muscle loss in numbers, even if the proportional loss is similar

Through better blood sugar management and promoting weight reduction, it indirectly supports better cardiovascular health, reducing the risk of heart-related issues

2012, 304 (4): H538-546